Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Effects of Curcumin-Piperine Supplementation in Fibromyalgia

sunnuntai 9. elokuuta 2026 päivittänyt: Marina Khalil, Ain Shams University

Evaluation of the Effect of Curcumin and Piperine Supplementation on Clinical Outcome in Fibromyalgia Patients.

The goal of this clinical trail is to evaluate the effectiveness and safety of curcumin-piperine supplementation in patients with fibromyalgia over 3 months compared to placebo.

Participants will:

Be randomly assigned to receive either curcumin and piperine supplements or a placebo.

Attend scheduled clinic visits for clinical assessments and blood sample collection.

Complete study questionnaires before and after treatment time frame.

The primary question the study aim to answer is:

Does Curcumin-piperine supplementation reduce pain intensity by Visual Analog Scale (VAS), compared with placebo?

The secondary questions this study aims to answer are:

Does supplementation improve fibromyalgia disease impact and quality of life? Does supplementation improve inflammatory biomarkers and oxidative stress? Does supplementation improve insulin resistance? Is curcumin and piperine supplementation safe and well tolerated?

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Yksityiskohtainen kuvaus

Fibromyalgia (FM) is a chronic pain disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive impairment, and mood disorders. Increasing evidence suggests that its pathogenesis is driven by a complex interaction of central sensitization, neuroinflammation, and oxidative stress. Elevated levels of pro-inflammatory cytokines and oxidative stress biomarkers have been linked to pain severity and disease progression. Although current pharmacological therapies can reduce symptoms, their effectiveness is often limited, and they do not adequately address the underlying biological mechanisms.

In addition to inflammation and oxidative stress, insulin resistance (IR) has recently emerged as a potential contributor to fibromyalgia. Several clinical studies have reported higher HOMA-IR values in patients with FM than in healthy individuals, with greater insulin resistance being associated with more severe pain and poorer clinical outcomes. This relationship may be explained by chronic low-grade inflammation, increased oxidative stress, impaired glucose metabolism, and altered central pain processing. These findings suggest that metabolic dysfunction may contribute to symptom persistence and represent an additional therapeutic target in FM.

Curcumin, a natural polyphenol extracted from "Curcuma longa", has attracted considerable interest because of its anti-inflammatory, antioxidant, neuroprotective, and analgesic properties. In addition to reducing inflammatory mediators, oxidative stress, and modulating pain pathways, curcumin has been shown to improve insulin sensitivity and glycemic control, suggesting that it may simultaneously target both the inflammatory and metabolic abnormalities associated with FM.

These findings support the hypothesis that curcumin may improve fibromyalgia by addressing inflammation, oxidative stress, pain sensitization, and metabolic dysfunction. However, current clinical evidence remains limited by small sample sizes and short intervention periods. Furthermore, curcumin's poor oral bioavailability can be markedly enhanced by co-administration with piperine, which increases its intestinal absorption. Therefore, a well-designed randomized controlled trial is needed to evaluate the efficacy and safety of curcumin-piperine supplementation as an adjunctive therapy for patients with fibromyalgia.

A total of 80 fibromyalgia patients will be enrolled in the study. Patients will be stratified according to insulin resistance status (insulin-resistant vs. non-insulin-resistant) followed by permuted block randomization to the study groups. All patients in both groups will receive standard treatment consisting of duloxetine and gabapentin, along with personalized guidance on an anti-inflammatory diet and exercise program.

Participants will be educated about the study and asked to sign a written informed consent before starting the study, assuring that they can withdraw at any time if they want.

The following data will be collected from patient records and by history taking from the patients upon enrollment:

A. Patient demographics including age, gender, weight, height, and body mass index (BMI).

B. Clinical variables including HbA1c, and HOMA-IR, complete blood picture, kidney function tests and liver function tests C. Comorbidities including but not limited to diabetes, hypertension, chronic kidney disease, cardiovascular disease, and immunosuppression.

D. Medical history including previous hospitalizations, surgeries, medication history, and known drug allergies.

E. Medication history including analgesic consumption (dose, frequency, and duration)

The patients will be followed up by weekly phone calls to encourage adherence and to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects reported by the patients throughout the trial. In addition, complete blood picture, kidney function tests, and liver function tests will be assessed at baseline, after 1 month and by the end of the study (after 3 months).

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

80

Vaihe

  • Vaihe 2

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Ismailia, Egypti, 41511
        • Suez Canal University hospitals
        • Ottaa yhteyttä:
          • Rheumatology and Rehabilitation Outpatient Clinic
          • Puhelinnumero: +201277884948
        • Päätutkija:
          • marina w khalil, M.Sc candidate
        • Alatutkija:
          • Maha Abd El-Fattah, Associate Professor of Rheumat

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  • Adult women aged ≥18 years.
  • Patients with confirmed diagnosis of fibromyalgia, according to 2022 ACR Fibromyalgia criteria.

Exclusion Criteria:

  • Diabetic patients (HbA1c ≥ 6.5).
  • Patients with chronic inflammatory or autoimmune diseases other than FM.
  • Patients allergic to curcumin or piperine.
  • Patients receiving other anti-inflammatory medications.
  • Severe hepatic or renal impairment.
  • Patients receiving anticoagulant medications (e.g., clopidogrel).
  • Pregnancy or lactation.
  • Participation in another clinical trial

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Group A (Curcumin Group)
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract), in addition to the standard treatment.
The experimental group will receive Organic Nation Curcumin® oral coated tablets, administered once daily for 3 months, containing 1,200 mg of standardized curcumin (95% turmeric extract) combined with 10 mg of piperine (95% black pepper extract).
Placebo Comparator: Group B (Placebo Group)
Participants will receive identical-appearing tablets containing inert excipients once daily for 3 months, in addition to the standard treatment.
the placebo group will receive matching oral placebo tablet containing inert excipients for the same duration. The placebo tablets will be identical in appearance, size, color, and packaging to the active supplement to maintain blinding.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Assessment of pain severity measured by the Visual Analog Scale (VAS)
Aikaikkuna: 3 months
VAS is a self-administered instrument widely used in fibromyalgia research and clinical practice to assess pain intensity and monitor treatment response. The VAS uses a 10-cm horizontal line anchored by 0 (no pain) and 10 (worst imaginable pain). It will be measured at baseline, after 1 month, and after 3 months.
3 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
The Revised Fibromyalgia Impact Questionnaire (FIQR)
Aikaikkuna: 3 months
is a disease-specific, patient-reported outcome measure designed to assess disease severity and the overall impact of fibromyalgia. It comprises 21 items grouped into three domains: function (9 items assessing physical activities), overall impact (2 items evaluating the extent to which fibromyalgia interferes with goal achievement and causes a feeling of being overwhelmed), and symptoms (10 items assessing pain, fatigue, sleep quality, stiffness, depression, anxiety, memory, balance, tenderness, and environmental sensitivity). All items are rated on a 0-10 numeric scale. The total FIQR score ranges from 0 to 100, with higher scores indicating greater disease impact and symptom severity. It will be measured at baseline, after 1 month, and after 3 months
3 months
The 36-Item Short Form Health Survey (SF-36)
Aikaikkuna: 3 months
SF-36 is a validated, self-administered, generic instrument used to assess health-related quality of life in fibromyalgia research by evaluating both physical and mental health status. It consists of 36 items covering eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. Domain scores are transformed to a scale ranging from 0 to 100, where 0 represents the worst and 100 the best perceived health status, and are aggregated into two summary measures: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). It will be measured at baseline, after 1 month, and after 3 months
3 months
Serum inflammatory biomarkers: IL-6
Aikaikkuna: 3 months
Collected serum samples will be stored at -80 C until analysis. Serum IL-6 will be assessed using enzyme-linked immunosorbent assay (ELISA) kits. It will be measured at the start and end of the study (after 3 months).
3 months
Serum oxidative biomarker: MDA
Aikaikkuna: 3 months
Collected serum samples will be stored at -80oC until analysis. Serum MDA will be assessed for each patient using spectrophotometric assay kits. It will be measured at the start and end of the study (after 3 months).
3 months
Glycemic markers: HOMA-IR
Aikaikkuna: 3 months
Insulin resistance will be assessed using the HOMA-IR ( fasting insulin × fasting glucose / 405), which is calculated from fasting glucose and fasting insulin levels. Fasting blood glucose will be measured using an enzymatic colorimetric method, and fasting serum insulin will be determined using ELISA kits.It will be measured at the start and end of the study (after 3 months).
3 months
The Hospital Anxiety and Depression Scale (HADS)
Aikaikkuna: 3 months
The scale consists of 14 self-reported items, divided equally into two domains: anxiety (HADS-A) and depression (HADS-D). Each item is rated on a 4-point Likert scale (0-3), yielding subscale scores ranging from 0 to 21, where higher scores indicate greater symptom severity. A cut-off score of ≥8 on either subscale is considered indicative of clinically relevant anxiety or depression. Elevated HADS scores in this population have been consistently associated with higher symptom severity, increased pain intensity, poorer sleep quality, reduced quality of life, and functional impairment. It will be measured at baseline, after 1 month, and after 3 months.
3 months
Incidence and severity of treatment-emergent adverse events
Aikaikkuna: 3 months
The patients will be followed up by weekly phone calls to evaluate the incidence and severity of the adverse effects including GIT disturbances or any other undesirable side effects.
3 months
Change in alanine aminotransferase (ALT) level
Aikaikkuna: 3 months
Serum alanine aminotransferase (ALT) level will be assessed at baseline and after 3 months. ALT will be reported in unit per liter (U/L)
3 months
Change in aspartate aminotransferase (AST) level
Aikaikkuna: 3 months
Serum aspartate aminotransferase (AST) level will be assessed at baseline and after 3 months. AST will be reported in unit per liter (U/L)
3 months
Change in serum creatinine level
Aikaikkuna: 3 months
Change in serum creatinine level will be assessed at baseline and after 3 months. Serum creatinine level will be reported in (mg/dL).
3 months
Change in hemoglobin level
Aikaikkuna: 3 months
Hemoglobin level will be assessed at baseline and after 3 months. Hemoglobin will be reported in (g\dL).
3 months
Change in white blood cell count
Aikaikkuna: 3 Months
white blood cell count will be assessed at baseline and after 3 months. white blood cell count will be reported as thousand cells per microliter
3 Months
Change in platelet count
Aikaikkuna: 3 months
Platelet count will be assessed at baseline and after 3 months. Platelet count will be reported as thousand cells per microliter.
3 months

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Lauantai 1. elokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Sunnuntai 20. kesäkuuta 2027

Opintojen valmistuminen (Arvioitu)

Sunnuntai 1. elokuuta 2027

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Tiistai 4. elokuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 4. elokuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Perjantai 7. elokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 11. elokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Sunnuntai 9. elokuuta 2026

Viimeksi vahvistettu

Lauantai 1. elokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa